Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 12/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | RELA | Q04206 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | STAT1 | P42224 | 1/20 | 0.61 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.61 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 4/20 | 0.60 |
| ▸ | MMP9 | P14780 | 4/20 | 0.60 |
| ▸ | MMP8 | P22894 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566197 | 0.87 | NPC1 (0.78) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2244388 | 0.86 | NPBWR1 (0.81) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31060181 | 0.84 | CHEK2 (0.82) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12470997 | 0.83 | NPBWR1 (0.82) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10172964 | 0.82 | NPBWR1 (0.80) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL28612020 | 0.82 | MMP2 (0.71) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3193088 | 0.82 | NPBWR1 (0.80) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3183535 | 0.82 | MAPT (0.66) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13856173 | 0.82 | NPBWR1 (0.80) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2308775 | 0.81 | NPBWR1 (0.79) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194981-B1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIV MONS HAINAUT (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2194981-B1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIV MONS HAINAUT (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| WO-2009043902-A1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIVERSITE DE MONS HAINAUT (BE) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | NQO2, SQOR, CPS1 | NPBWR1 1299/4885NPC1 1415/4885MAPT 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.